NewswireToday - /newswire/ -
Charlotte, NC, United States, 2010/12/06 - Biotage announces the addition of ChemMatrix® resins to its extensive offering of peptide synthesis and purification products. ChemMatrix offers substantial advantages over traditional PS and PEG based resins for solid phase peptide synthesis.
Biotage® (STO: BIOT), a leading supplier of tools and technology for analytical and medicinal chemistry, announced the addition of ChemMatrix® resins to its extensive offering of peptide synthesis and purification products. ChemMatrix is a patented 100% PEG resin from PCAS BioMatrix that offers substantial advantages over traditional PS and PEG based resins for solid phase peptide synthesis.
“Biotage is a leader in the global development of tools and technology for peptide synthesis and purification. Earlier this year, we introduced the SyroWave® peptide synthesizer, more recently Resolux™ HPLC columns for peptides purification and now ChemMatrix resins.” says Scott Carr, VP of Commercial Operations. “Biotage truly delivers a total solution to professionals in this growing area of science.”
The ChemMatrix resin is a technological tool enabling synthesis of complex molecules from biological origin, peptides, oligionucleotides and small proteins typically used for therapeutic purposes. This resin is supplied as classical spherical beads, a tried and tested solution in the industry for almost 50 years but leverages today’s need for flexibility and exacting standards of quality and performance in the synthesis of especially difficult sequences.
There are many benefits to ChemMatrix, such as; exceptional stability, wide solvent compatibility, no leaching, optimum loading capacity allow users to achieve higher purities and yields of product, per gram of resin, especially in the case of difficult peptide sequences.
Biotage (biotage.com) offers solutions, knowledge and experience in the areas of analytical and medicinal chemistry. The customers include the world’s top pharma and biotech companies, as well as leading academic institutes. The company is headquartered in Uppsala, Sweden, and has offices in the United States, United Kingdom and Japan. Biotage has 245 employees and had sales of SEK 394,1m in 2009. Biotage is listed on the NASDAQ OMX Nordic Stock Exchange.